Drug Database
ES

escitalopram + clonazepam (Citapure Forte)

✓ Approved

A. N. Pharmacia Laboratories · GABRA1 · Small Molecule

What is escitalopram + clonazepam?

escitalopram + clonazepam is a small molecule developed by A. N. Pharmacia Laboratories. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCitapure Forte
CompanyA. N. Pharmacia Laboratories
Drug ClassSmall Molecule
Molecular TargetGABRA1, GABRA2, GABRA3, GABRA4, SLC6A4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, A. N. Pharmacia Laboratories

Mechanism of Action

Molecular Targets

escitalopram + clonazepam acts on 5 molecular targets:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (ECA4, EJM)
GABRA2gamma-aminobutyric acid type A receptor alpha2 subunit (EIEE78, DEE78)
GABRA3gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4gamma-aminobutyric acid type A receptor alpha4 subunit ()
SLC6A4solute carrier family 6 member 4 (SERT1, 5-HTTLPR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

escitalopram + clonazepam is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersBipolar I disorder✓ Approved
Psychiatric disordersGeneralised anxiety disorder✓ Approved

Related Research Articles

PubMedNature. Mental health2026-07-16

Generalizable structure-function covariation predictive of antidepressant response revealed by target-oriented multimodal fusion.

Tong Xiaoyu X, Zhao Kanhao K, Fonzo Gregory A GA, Xie Hua H et al.

Major depressive disorder (MDD) is a prevalent condition that profoundly impairs quality of life across diverse populations. Despite widespread use, current antidepressant and psychotherapeutic treatments exhibit limited efficacy and unsatisfactory response rates. Progress in developing effective therapies is hampered by the insufficiently understood heterogeneity of MDD and its elusive underlying mechanisms. Here, to address these challenges, we develop a novel machine learning framework that identifies structure-function covariation through target-oriented fusion of structural and functional connectivity, which robustly predicts individual-level antidepressant response (sertraline, R 2 = 0.31; placebo, R 2 = 0.22). Validation in an independent escitalopram-medicated MDD cohort confirms the biomarker's generalizability (P = 0.01) and suggests an overlap of psychopharmacological signatures across selective serotonin reuptake inhibitors. Our models highlight the right precuneus as a common key region for both sertraline and placebo responses, with the right middle frontal gyrus and left fusiform gyrus specific to sertraline and the left inferior and middle frontal gyri to placebo. We also find that structural connectivity is more predictive of sertraline response, while functional connectivity better predicts placebo response. The framework further decomposes the overall predictive patterns into three constitutive network constellations (default-mode regulatory, affective and sensory processing), which exhibit distinct generalizable structure-function covariation and treatment-specific association with personality traits and behavioral/cognitive profiles. These findings provide unique insights to the structure-function covariation in patients with MDD, its association to the heterogeneity in antidepressant response and the dissection of the intricate MDD neuropsychopharmacology, paving the way for precision medicine and development of more targeted antidepressant therapeutics. Clinicaltrials.gov registration: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC), NCT01407094.

PMID 42460432
Read full article →
PubMedJournal of family medicine and primary care2026-07-15

A comparative analysis of vortioxetine vs. escitalopram on the clinical profile of patients with major depressive disorder.

Mishra Saloni S, Shah Kashyap K, Menon Manisha M, Mudgal Varchasvi V et al.

Major depressive disorder (MDD) remains a leading cause of disability worldwide, necessitating effective pharmacological treatments. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram and newer antidepressants like vortioxetine are commonly prescribed for managing MDD. Although both medications are widely used, comparative data on their clinical and cognitive efficacy remains limited. This study aims to compare the clinical effectiveness of escitalopram and vortioxetine in alleviating depressive symptoms, with a particular focus on symptom reduction over a 4-week treatment period. This was a prospective, randomized, open-label study conducted at a tertiary care center from October 2023 to October 2024. A total of 100 patients diagnosed with MDD were randomly assigned to receive either escitalopram (10 mg/day, n = 50) or vortioxetine (10 mg/day, n = 50). Symptom severity was assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline, 2 weeks, and 4 weeks. Statistical significance was evaluated using appropriate tests. Both Escitalopram and Vortioxetine produced significant reductions in HAM-D scores over the 4-week period. By Week 4, escitalopram demonstrated a statistically significant superior effect in symptom reduction compared to vortioxetine (mean HAM-D score: 14.22 vs. 16.32, P = 0.04). Both escitalopram and vortioxetine effectively reduce depressive symptoms in patients with MDD, with escitalopram showing a more rapid onset of symptom relief. Further long-term studies are warranted to assess the sustained efficacy and cognitive benefits of both medications in diverse patient populations.

PMID 42453242
Read full article →
PubMedJournal of clinical medicine2026-07-15

Study on the Gut-Brain Mechanism of Escitalopram for Alleviating Symptoms of Disorders of Gut-Brain Interaction in the Elderly-A Cohort Study.

Tang Qiao Q, Li Jing J

Objective: Disorders of gut-brain interaction (DGBIs) are characterized by functional impairments without identifiable organic causes, with their prevalence increasing with age. Emerging evidence suggests that selective serotonin reuptake inhibitors (SSRIs), such as escitalopram oxalate, may influence DGBIs through the brain-gut axis, though the precise mechanisms driving their therapeutic effects remain unclear. This study investigated the impact of escitalopram oxalate on elderly patients with DGBIs in an outpatient department to elucidate these mechanisms. Methods: This study was an observational cohort study. We recruited elderly patients diagnosed with DGBIs. Patients receiving standard treatment alone were assigned to the control group, while patients receiving standard treatment plus 10 mg of escitalopram oxalate daily were assigned to the exposure group. Emotional and gastrointestinal symptoms were assessed at baseline and after 12 weeks of treatment using validated symptom scales. Additionally, stool samples were collected at both time points and analyzed via 16S amplicon sequencing to evaluate the changes in gut microbiota. Results: A total of 83 elderly patients with DGBIs were included in the study, comprising 40 patients in the control group and 43 in the exposure group. After 12 weeks, the exposure group showed significantly greater reductions in their scores on the Gastrointestinal Symptom Rating Scale (GSRS), Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ), Zung Self-Rating Depression Scale (SDS) and Zung Self-Rating Anxiety Scale (SAS) compared with the control group (e.g., GSRS: 17.00 ± 0.85 vs. 22.58 ± 3.18, p < 0.001; p < 0.01 for all other scale comparisons), with higher effective and recovery rates. Notably, the exposure group showed significant alterations in the abundance of four genus-level taxa (Blautia, Butyricicoccus, Prevotellaceae UCG-003, and Streptococcus) and two species-level taxa (Eubacterium-hallii-group and Parabacteroides-merdae). Conclusions: The escitalopram oxalate treatment was associated with significant improvements in both emotional and gastrointestinal symptoms in elderly patients with DGBIs. These improvements may be linked to alterations in specific gut microbiota taxa, offering a preliminary hypothesis for further investigating the underlying mechanisms of the gut-brain axis.

PMID 42452560
Read full article →
PubMedJournal of intellectual disability research : JIDR2026-07-15

Prevalence of Psychotropic Use and Psychotropic Polypharmacy in a Finnish National Cohort of Persons With Intellectual Disabilities.

Virtanen Ville V, Saastamoinen Leena L, Arvio Maria M, Vesala Hannu T HT et al.

Psychotropic use and psychotropic polypharmacy are common in people with intellectual disabilities, but representative population-based studies on this topic are scarce. We evaluated the prevalence of psychotropic use and psychotropic polypharmacy in a Finnish nationwide cohort of people with intellectual disabilities aged 0-97 years. The annual prevalence of psychotropic use in 2019 was studied among 37 196 individuals with intellectual disabilities and an age- and sex-matched comparison cohort with no diagnosis of intellectual disabilities. Psychotropics included antipsychotics, antidepressants, anxiolytics, hypnotics and sedatives and antiepileptics indicated for bipolar disorder (carbamazepine, valproic acid, lamotrigine, pregabalin and clonazepam). Prevalence of interclass psychotropic polypharmacy (use from ≥ 2 different psychotropic groups) was evaluated in a 4-month time window at the end of 2019. Prevalence of psychotropic use was higher in the intellectual disability cohort (42.3%) than comparison cohort (15.0%). Antipsychotics were the most common psychotropic group in the intellectual disability cohort (28%), with lower prevalence in the comparison cohort (3.3%). The prevalence of antidepressant use was 19.4% in the intellectual disability cohort and 9.7% in the comparison cohort. A likely indication was identified for 52.9% of psychotropic users with intellectual disability (major psychiatric comorbidity 38.1%, challenging behaviour 22.1%). Psychotropic polypharmacy was more common in the intellectual disability cohort (18.2%), than in the comparison cohort (3.6%). Our findings highlight concerns about psychotropic polypharmacy and potential overmedication. Using a comprehensive, nationwide cohort, this study emphasises the need for more evidence-based, person-centred approaches, including careful diagnostics, non-pharmacological interventions and regular treatment reviews.

PMID 42454604
Read full article →
PubMedFrontiers in immunology2026-07-11

Sequential efgartigimod and ofatumumab for stiff-person syndrome: a case report illustrating a pathophysiology-informed strategy and literature review.

Yang Chenxi C, Zhou Junqiu J, Jiang Haishan H

Stiff-person syndrome (SPS) is a rare, antibody-mediated autoimmune disorder of the central nervous system, most frequently associated with antibodies against glutamic acid decarboxylase 65 (GAD65). Management of patients with an insufficient response to conventional immunotherapy remains a clinical challenge. We report a 40-year-old woman with anti-GAD65 antibody-positive SPS. She experienced severe relapse and functional disability (modified Rankin Scale [mRS] score 4) despite plasma exchange and maintenance immunosuppression. We designed a sequential, mechanism-base regimen: the neonatal Fc receptor antagonist efgartigimod (3 cycles) was administered to rapidly reduce pathogenic IgG, followed by the anti-CD20 monoclonal antibody ofatumumab (2 cycles) to deplete B-cells and provide sustained immunomodulation. This sequential strategy resulted in substantial and sustained clinical improvement (mRS score 4 to 1, Barthel Index 75 to 100) and a reduced clonazepam requirement despite persistently high anti-GAD65 antibody titers, demonstrating efficacy beyond mere antibody reduction. The regimen was well-tolerated with no significant adverse events. This case provides preliminary clinical experience with a sequential efgartigimod-ofatumumab strategy in treatment-resistant SPS. This approach, which combines rapid antibody clearance with sustained B-cell suppression, not only affirms the role of ofatumumab in long-term immunomodulation but also highlights the potential synergy of sequential administration, warranting further investigation.

PMID 42433377
Read full article →
PubMedSubstance use & addiction journal2026-07-09

Correlation of Illicit Opioid Use With Antidepressants in Adults Receiving Buprenorphine/Naloxone: An Exploratory Analysis.

Elarabi Hesham Farouk HF, Marsden John J, Adem Abdu A, Al Ghafri Hamad H et al.

Depression and anxiety are highly prevalent among individuals with opioid use disorder (OUD), and antidepressants are frequently prescribed in conjunction with medication for opioid use disorder. However, the relationship between specific antidepressants and continued illicit opioid use during buprenorphine-based treatment remains insufficiently characterized. This exploratory analysis aimed to investigate the association between prescribed antidepressants and illicit opioid use among adults with OUD receiving buprenorphine/naloxone. This sub-analysis included 92 participants from a randomized controlled trial of 141 adults with OUD treated with buprenorphine/naloxone over 16 weeks in an outpatient setting. Participants were eligible if they received at least one antidepressant for a minimum duration of 10 days. Depressive and anxiety symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7), respectively. The primary outcome was the proportion of urine drug screens positive for illicit opioids. Point-biserial correlation analyses were conducted to examine associations between individual antidepressants and illicit opioid use. Antidepressants demonstrating significant associations were subsequently included in multivariable linear regression models adjusted for age, treatment allocation group, and buprenorphine elimination rate constant. Interaction effects were also examined. The mean (SD) PHQ-9 score was 10.0 (5.4), and the median (IQR) GAD-7 score was 5.5 (2.0-13.75). Escitalopram 10 mg was the only antidepressant significantly associated with illicit opioid use, demonstrating a negative correlation (rpb = -.28). Multivariable regression analyses indicated that escitalopram exposure and older age were independently associated with a lower proportion of opioid-positive urine tests. A statistically significant interaction between escitalopram exposure and age was observed. Exposure to escitalopram 10 mg was associated with reduced illicit opioid use among individuals receiving buprenorphine/naloxone, with the magnitude of this association modified by age. Further large-scale prospective studies are warranted to confirm these findings and to elucidate the underlying mechanisms.

PMID 42423162
Read full article →

+8251 more articles available with a free account

Sign up free to view all articles →

Ask about escitalopram + clonazepam